



Research Article

## A RANDOMIZED CLINICAL TRIAL OF GOKSHURADI GHAN VATI AND GOKSHURADI RASAYANA CHURNA ALONG WITH SWARJIKADYA TAILA KARNA PICHU IN THE MANAGEMENT OF KARNASRAVA WITH SPECIAL REFERENCE TO CHRONIC SUPPURATIVE OTITIS MEDIA

Seema Yadav<sup>1\*</sup>, Gulab Chand Pamnani<sup>2</sup>, Aparna Sharma<sup>2</sup>

<sup>1</sup>Assistant Professor, Dept. of Shalakya Tantra, Punjab Ayurved Medical College and Hospital, Morjand Khari, Sri Ganganagar, Rajasthan.

<sup>2</sup>Associate Professor, Dept. of Shalakya Tantra, National Institute of Ayurveda, Deemed to be University, Jaipur, Rajasthan, India.

### Article info

#### Article History:

Received: 21-12-2022

Revised: 17-01-2023

Accepted: 03-02-2023

#### KEYWORDS:

Karnasrava, Gokshuradi Ghan Vati, Gokshuradi Rasayana Churna, Swarjikadya Taila, Karna Pichu.

### ABSTRACT

*Karnasrava* means flow, oozing, dropping, exudate or discharge through ear. *Karnasrava* correlates in modern science with C.S.O.M. C.S.O.M. are a chronic inflammation of the middle ear which is the result of an initial episode of acute otitis media and characterized by recurrent discharge from the middle ear through a tympanic perforation. According to WHO prevalence of C.S.O.M. involves 65-330 million individuals with draining ears, 60% of whom (39-200 million) suffers from significant hearing impairment. **Material and Method:** The present study is done with 30 patients of *Karnasrava* divided into two groups, 15 patients were treated with *Gokshuradi Ghan Vati* along with *Swarjikadya Taila Karna Pichu* rest 15 were treated with *Gokshuradi Rasayana Churna* along with *Swarjikadya Taila Karna Pichu*. **Result:** It showed that *Gokshuradi Ghana vati* along with *Swarjikadya Taila Karna Pichu* showed slightly significant as compared to *Gokshuradi Rasayana Churna* along with *Swarjikadya Taila Karna Pichu*. **Discussion:** *Swarjikadya Taila* is acts as *Sthanika Snehana* and *Swedana*, thus causes increased local warming, pseudo-inflammation and increased blood circulation there by helping in better absorption to affected site. Most of the drugs of *Gokshuradi Ghana Vati* have *Rasayana*, *Kasa-Shwashara*, *Vedanasthapana*, *Shulaprasmana*, *Shothahara*, *Balya*, *Vranashodhana*, *Vranaropana*, *Krimighna*, *Deepana*, *Pachana* properties. **Conclusion:** Both groups showed good result in the management of *Karnasrava* but *Gokshuradi Ghana vati* along with *Swarjikadya taila Karna pichu* showed slightly significant as compared to *Gokshuradi Rasayana Churna* along with *Swarjikadya Taila Karna Pichu*.

### INTRODUCTION

Ears are prone to 28 different kinds of ailments (according to *Sushruta*) and *Karnasrava* is one of them<sup>[1]</sup>. *Acharya Charaka* included *Karnasrava* as a symptom under the four types of *Karnarogas* due to vitiation of different *Doshas*<sup>[2]</sup>. *Acharya Vagbhatta* has not described *Karnasrava* separately *Karnasrava* means flow, oozing, dropping, exudate or discharge through ear. According to *Sushruta Karnasrava* is

discharge of pus from a *Vata* affected ear may result from head injury or due to immersion in water or else due to suppuration or bursting of an abscess<sup>[3]</sup>.

Other causes like *Avasyaaya* (dew), *Pratishyaya* (common cold), *Mithyayogena shsastrasya*, *Mithyayogena shabdasya* are also included by *Sushruta*. *Karnasrava* can correlate in modern science with C.S.O.M. C.S.O.M. is a chronic inflammation of the middle ear which is the result of an initial episode of acute otitis media and characterized by recurrent discharge from the middle ear through a tympanic perforation. A history of at least 2 weeks of persistent ear discharge is pointed towards CSOM, if the ear could be dry mopped to see the ear drum, then the diagnosis of C.S.O.M. can be confirmed by observing the perforation in the tympanic membrane. C.S.O.M. is

#### Access this article online

Quick Response Code



<https://doi.org/10.47070/ayushdhara.v10iSuppl1.1168>


Published by Mahadev Publications (Regd.) publication licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0)

Website: <https://ayushdhara.in>

defined as irreversible changes within the mucosa of middle ear. More prone groups for C.S.O.M. are lower socioeconomic status (due to poor nutrition and lack of health education), upper respiratory tract infections, swimming and diving, traumatic perforation of tympanic membrane, infections of tonsils and adenoids, chronic rhinitis and sinusitis, nasal allergy, cleft palate, exanthematous fevers (like measles, diphtheria, whooping cough), living in overcrowded conditions, history of multiple episodes of acute otitis media etc.

According to *Acharya Sushruta Uttartantra* 21/40- *Karnasrava* is treated by *Shirovirechana (Nasya)*, *Dhupana*, *Poorana*, *Pramarjana*, *Dhaavana* and oral drug therapy etc<sup>[4]</sup>. In modern science patients of C.S.O.M. are treated with topical antiseptics or antibiotics after cleaning the ear canal for at least 2 weeks, administering antibiotics, anti-pseudomonal drugs etc. Patients having intracranial and extra cranial infections are more appropriately treated with surgery.

#### Samprapti of Karnasrava<sup>[5]</sup>



#### Need for Study

According to WHO prevalence, global burden of C.S.O.M. involves 65-330 million individuals with draining ears, 60% of whom (39-200 million) suffers from significant hearing impairment. C.S.O.M. accounts for 28,000 deaths. It is an important cause of preventable hearing loss particularly in the developing world<sup>[6]</sup>. In modern science, mostly treatment approach of C.S.O.M. have been surgical, expensive, difficult and does not lead to satisfactory hearing improvement and inaccessible in many developing countries. C.S.O.M. is one of the most common complain encountered in clinical practice of ENT<sup>[7]</sup>.

Considering all these points, there is a need to search an effective, preventive and safe treatment. In classical text appealable formulations are described under *Karnaroga Chikitsa*. Hence there is definitely a

scope of research for better solution in the disease *Karnasrava*.

#### AIM AND OBJECTIVE

##### Aim

1. To evaluate the efficacy of Ayurvedic drugs on *Karnasrava* w.s.r. to C.S.O.M.

##### Objectives

1. To evaluate the efficacy of *Gokshuradi Ghan Vati* on *Karnasrava* w.s.r. to C.S.O.M.
2. To evaluate the efficacy of *Gokshuradi Rasayana Churna* on *Karnasrava* w.s.r. to C.S.O.M.
3. To evaluate the efficacy of *Swarjikadya Taila Karna Pichu* on *Karnasrava* w.s.r. to C.S.O.M.

#### MATERIAL AND METHOD

**Conceptual Study:** There was critical review of relevant literature in Ayurveda and modern text books, previous research papers and thesis.

##### Clinical Study

##### Selection of Cases

**Source:** The study was conducted on 30 clinically diagnosed patients of *Karnasrava* from OPD/IPD of *Shalaky Tantra* Department, NIA, Jaipur.

**CTRI Registration Number** - CTRI/2021/07/035178

##### Inclusion Criteria

Patient having specific signs and symptoms of *Karnasrava* (C.S.O.M.) on Ayurvedic and modern parameters were registered for the present clinical trial.

Age - 7 years to 70 years

##### Exclusion Criteria

- Systemic diseases like uncontrolled DM, meningitis, tuberculosis, HTN etc.
- History of long term intake of ototoxic drugs
- Pregnant women
- C.S.O.M. with complications like- acute mastoiditis, petrositis, facial paralysis, adenoids, tonsillitis, labyrinthitis etc.
- Traumatic perforation of tympanic membrane.

##### Diagnostic Criteria

- **Symptom:** *Karnasrava* (ear discharge)
- **Associate Symptom:** *Badharya* (conductive hearing loss) and *Karnakandu*.

##### Plan of Study

1. **Proforma:** A particular proforma was prepared to maintain the records of the whole observations regarding the disease.
2. **Investigation:** Following investigations were carried out to assess the condition and to exclude any other pathology of the patients.

##### Laboratory investigation

CBC, FBS, Ear Swab Culture and Sensitivity

### Grouping of Patients

Total 30 patients with signs and symptoms of Karnasrava (C.S.O.M.) were registered and randomly divided into two groups irrespective of their age, sex, occupation, religion, socioeconomic status etc.

- **Group A:** 15 patients were treated with *Gokshuradi Ghan Vati* along with *Swarjikadya Taila Karna Pichu*.
- **Group B:** 15 patients were treated with *Gokshuradi Rasayana Churna* along with *Swarjikadya Taila Karna Pichu*.

### The description of individual drugs is as follows

#### 1) *Gokshuradi Ghan Vati*<sup>[8]</sup>- (*Astang Hridaya Uttartantra 39/160*)

Sr.No.	Drugs	Botanical Name	Part Used	Quantity
1.	<i>Gokshura</i>	<i>Tribulus terrestris</i> Linn	Fruit	1 Part
2.	<i>Amalaki</i>	<i>Emblica officinalis</i> Gaertn	Fruit	1 Part
3.	<i>Guduchi</i>	<i>Tinospora cordifolia</i> (willd)	Stem	1Part

#### 2) *Gokshuradi Rasayana Churna*<sup>[9]</sup>- (*Astanghridaya Uttartantra 39/160*)

Sr.No.	Drugs	Botanical Name	Part Used	Quantity
1.	<i>Gokshura</i>	<i>Tribulus terrestris</i> Linn	Fruit	1 part
2.	<i>Amalaki</i>	<i>Emblica officinalis</i> Gaertn	Fruit	1 part
3.	<i>Guduchi</i>	<i>Tinospora cordifolia</i> (willd)	Stem	1 part

#### 3) *Swarjikadya Taila*<sup>[10]</sup>- (*Bhaishajya- Ratnavali Chi. 62/27*)

Sr.No	Drugs	Botanical Name	Part Used	Quantity
1.	<i>Swarjika</i>	Na <sub>2</sub> CO <sub>3</sub>	Powder	1 Part
2.	<i>Mulaka</i>	<i>Raphanus sativus</i> Linn.	Rhizome	1 Part
3.	<i>Hingu</i>	<i>Ferula northex</i> Boiss.	<i>Niryasa</i>	1Part
4.	<i>Krishna</i>	<i>Piper longum</i> Linn.	Fruit	1Part
5.	<i>Mahoashadha</i>	<i>Zingiber officinale</i> Rosc.	Rhizome	1Part
6.	<i>Satpushpa</i>	<i>Anethum sowa</i> Kurz.	Fruit	1Part

### Drug, Dose and Duration of Trial

#### 1. *Gokshuradi Ghan Vati*

- Adult dose- (500mg) twice a day, orally (after meal)
- Children dose- 250mg twice daily, orally (after meal)
- Duration- 30 days
- *Anupaan* - Milk

#### 2. *Gokshuradi Rasayana Churna*

- Adult dose- 5gm twice a day, orally (after meal)
- Children dose- 3gm twice a day, orally (after meal)
- Duration- 30 days
- *Anupaan* - *Madhu* & *Ghrita*

#### 3. *Swarjikadya Taila* - 1ml each in ear canal twice a day in *Pichu* form.

- Duration - 30 days (3 sitting of 7 days with an interval of 3 days in each sitting)

**Follow Up** - 15 days

**Total Duration of Study** - 30 days

### Assessment Criteria

The results of the clinical trial were assessed, based on the observations of clinical features and laboratory findings. Following parameters were adopted for assessing the patients before, during and after treatment.

### Subjective

Following signs and symptoms were examined during the course of therapy.

- *Karnasrava* (Presence/absence of discharge)
- *Badharya* (Conductive hearing loss)
- *Karnakandu* (Itching in ear)

**Objective**

Following objectives were assessed before and after trial.

- Otoscopy
- Ear Swab Culture and Sensitivity
- Pure Tone Audiometry

**Present study had been planned with following criteria:**

Assessment was done on the basis of improvement in the clinical condition of the patient. A specific scoring pattern was adopted to assess the improvement.

S.No.	Subjective	BT	AT	Follow up 15 days
1.	<i>Karnasrava</i>			
2.	<i>Badhirya</i>			
3.	<i>Karna kandu</i>			

**Subjective symptoms were assessed with the help of following scoring pattern - Grading**

<b>Ear discharge quantity</b>	
Grade-0	Nil/Absent
Grade-1	Scanty (seen on the tip of cotton bud)
Grade-2	Moderate (feeling of discharge in ear, needs moping)
Grade-3	Profuse (discharge comes outside)
<b>Consistency of Ear discharge</b>	
Grade-0	Nil/Absent
Grade-1	Serous/ Muroid
Grade-2	Mucopurulent
Grade-3	Sanguineous
<b>Karnakandu (Itching in ear)</b>	
Grade-0	Nil / Absent
Grade-1	Occasional itching
Grade-2	Continuous mild itching
Grade-3	Continuous severe itching

**Objective symptoms were assessed with the help of following scoring pattern**

S.N.	Objective	BT	AT	Follow up 15 <sup>th</sup> day
1.	Pure Tone Audiometry			
2.	TM assessment (otoscopy)			
3.	Swab culture			

<b>Badhirya (Hearing Loss)</b>	
Grade-0	Normal Hearing
Grade-1	Able to hear when there is discharge
Grade-2	Diminished hearing irrespective of discharge
Grade-3	Severe hearing loss persists through out
<b>Pure Tone Audiometry</b>	
Grade-0	0-25 dB
Grade-1	26-40 dB
Grade-2	41-60 dB
Grade-3	61-80 dB
Grade-4	81dB or greater
<b>Swab culture</b>	
Grade-0	Micro-organisms absent
Grade-1	Micro-organisms present



## OBSERVATION AND RESULT

### Observation

- In the present study, it was observed that majority of patients (80%) were having *Avashyaya* as *Nidana* followed by 53.33% of patients having *Jalakrida Nidana Sevana*.
- It was observed that maximum number of patients (41.17%) were found infected with *Stephylococcus aureus*, 20.58% of patients had no growth, 17.64% of patients infected with *Coagulase negative staphylococcus*, 11.76% of patients were infected with *Pseudomonas*, 5.88% of patients were infected with *E. Coli*, 2.94% of patients were infected with *Enterococcus* bacterial infection. Data shows that *Stephylococcus* infection is common in the patients of *Karnasrava*.
- It was observed that maximum number of patients (93.33%) had gradual onset of *Karnasrava*, with unilateral ear involvement (86.67%), continuous *Srava* (53.33%), moderate quantity (73.33%), yellow colour (80%), and purulent discharge (53.33%) and without smell (100%).
- Maximum number of patients had unilateral (53.33%) ear involvement in *Karnakandu*, intermittent *Karnakandu* (60%), mild severe *Karnakandu* (60%) and 53.33% of patients had *Karnakandu* in non-specific.
- Majority of patients (63.33%) had gradual hearing loss, 53.33% of patients had mild hearing loss and 60% of patients had gradual onset of *Badhirya*.

### RESULT

**Table 1: Effect of therapy on subjective parameters in Group A (n=15, Wilcoxon Sign Rank test)**

Parameters	BT	AT	M.D	% of Change	SD	SE	W	P	S
<i>Karnasrava</i> Quantity	1.73	0.13	1.6	92.30	0.50	0.13	120	<0.001	HS
<i>Karnasrava</i> Consistency	1.80	0.13	1.67	92.59	0.48	0.12	120	<0.001	HS
<i>Badhirya</i>	0.66	0.53	0.13	20.00	0.35	0.09	3.00	>0.05	NS
<i>Karnakandu</i>	1.26	0.33	0.93	73.68	0.25	0.06	105	<0.001	HS

**Table 2: Effect of therapy on subjective parameters in Group B (n=15, Wilcoxon Sign Rank test)**

Parameter	BT	AT	Mean Diff.	% of Change	SD	SE	W	P	S
<i>Karnasrava</i> Quantity	2.06	0.86	1.2	58.06	0.41	0.10	120	<0.001	HS
<i>Karnasrava</i> Consistency	2.13	0.93	1.2	56.25	0.56	0.14	105	<0.001	HS
<i>Badhirya</i>	0.86	0.80	0.06	7.69	0.25	0.06	1.00	>0.05	NS
<i>Karnakandu</i>	1.06	0.40	0.66	62.50	0.81	0.21	28.00	<0.05	S

**Table 3: Effect of therapy on objective parameters in Group A (n=15, paired t test)**

Parameters	BT	AT	% of Change	SD	SE	T	P	S
Hb	13.24	13.21	0.20	0.21	0.05	0.03	>0.05	NS
TLC	7.72	7.32	5.26	0.40	0.10	0.26	<0.05	S
Neutrophils	56.64	56.18	0.80	4.19	1.08	0.02	>0.05	NS
Lymphocytes	32.85	30.86	6.04	3.14	0.81	0.16	<0.05	S
Monocytes	6.60	6.10	7.57	0.76	0.19	0.16	<0.05	S
Eosinophils	3.86	3.77	2.43	0.36	0.09	0.06	>0.05	NS
Basophils	0.75	0.54	27.43	0.33	0.08	0.15	<0.05	S
FBS	84.18	83.99	0.22	2.06	0.53	0.02	<0.05	S
Pure Tone Audiometry	0.66	0.60	10.00	0.24	0.06	0.06	>0.05	NS
TM Assessment by Otoscope	1.40	1.20	14.28	0.40	0.10	0.12	>0.05	NS
Swab culture	0.86	0.40	53.84	0.61	0.15	0.19	<0.05	S

**Table 4: Effect of therapy on objective parameters in Group B (n=15, paired t test)**

Parameters	BT	AT	% of Change	SD	SE	T	P	S
Hb	14.27	14.26	0.04	0.11	0.02	0.01	>0.05	NS
TLC	7.24	7.28	0.45	0.37	0.09	0.02	>0.05	NS
Neutrophils	56.34	56.73	0.69	4.05	1.04	0.02	>0.05	NS
Lymphocytes	30.61	28.15	8.05	4.81	1.24	0.13	>0.05	NS
Monocytes	8.21	7.42	9.65	0.82	0.21	0.24	<0.05	S
Eosinophils	3.72	3.64	2.32	0.85	0.22	0.02	>0.05	NS
Basophils	0.71	0.56	20.56	0.18	0.04	0.20	<0.05	S
FBS	89.17	87.45	1.93	3.10	0.80	0.14	<0.05	S
Pure Tone Audiometry	0.87	0.80	7.69	0.24	0.06	0.06	>0.05	NS
TM Assessment by Otoloscope	1.46	1.26	13.63	0.40	0.10	0.12	>0.05	NS
Swab culture	0.93	0.46	50.00	0.49	0.12	0.24	<0.05	S

**Comparative results**

**Table 5: Comparative effect of both the groups in subjective parameters (n=30, Mann Whitney U Test)**

Parameters (n=30)	Mean		U'	P	S
	Group A	Group B			
<i>Karnasrava</i> Quantity	1.60	1.20	67.50	<0.05	S
<i>Karnasrava</i> Consistency	1.67	1.20	65.00	<0.05	S
<i>Badhirya</i>	0.06	0.06	112.50	>0.05	NS
<i>Karnakandu</i>	0.93	0.80	97.50	>0.05	NS

**Table 6: Comparative effect of both the groups in Objective Parameters (n=30, unpaired T Test)**

Parameters (n=30)	Mean		T	P	S
	Group A	Group B			
Hb	0.02	0.06	0.32	>0.05	NS
TLC	0.41	0.03	3.10	<0.05	S
Neutrophils	0.45	0.39	0.56	>0.05	NS
Lymphocytes	1.98	2.46	0.32	>0.05	NS
Monocytes	0.50	0.79	1.01	>0.05	NS
Eosinophils	0.09	0.08	0.02	>0.05	NS
Basophils	0.20	0.14	0.61	>0.05	NS
FBS	0.19	1.72	1.59	>0.05	NS
Pure Tone Audiometry	0.06	0.06	0.00	>0.05	NS
TM Assessment by Otoloscope	0.20	0.20	0.00	>0.05	NS
Swab culture	0.46	0.46	0.00	>0.05	NS

**Table 7: Overall Effect of Therapy**

Effect of therapy	Group A	%	Group B	%	Total	Total %
Marked improvement	06	40.00	02	13.33	08	26.67
Moderate improvement	07	46.67	09	60.00	16	53.33
Mild improvement	02	13.33	04	26.67	06	20.00

## DISCUSSION

### Discussion on Trial Drugs with Their Probable Mode of Action

#### Gokshuradi Ghana Vati and Gokshuradi Rasayana Churna

- *Gokshuradi Ghana vati* and *Gokshuradi Rasayana Churna* has 3 contents- *Gokshur*, *Amalaki* and *Guduchi*. (one part each ) (*Astanga Hardayam* of *Shrimad Vagbhata* edited with *Nirmala Hindi Commentary* by Dr. Brahmanand Tripathi, Chaukhamba Sanskrit Pratishtan Delhi, *Astanghridaya Uttartantra* 39/160). Most of the drugs of *Gokshuradi Ghana Vati* have *Rasayana*, *Kasa-Shwashara*, *Vedanasthapana*, *Shulaprashmana*, *Shothahara*, *Balya*, *Vranashodhana*, *Vranaropana*, *Krimighna*, *Deepana*, *Pachana* properties. In *Karnasrava*, *Avashyaya* is main *Nidana* which is *Vata* dominant and here most of the drugs have *Kapha-Vata Shamaka* properties, *Guduchi* has *Tridosha Shamaka* properties, which helps in *Samprapti Vighatana*. Here all the drugs have *Ushna Virya* properties which enhances local as well as general metabolism of body. It also helps in drying up the *Srava* and gives quick action of drug. Most of the drugs have antioxidant and nervine tonic properties which help in prevention of cochlear damage or further *Badharya*. It is proved that *Guduchi* has immune-modulator effect, which helps in boosting up the immune system and prevention of repeated infections<sup>[14]</sup>. Considering all these points it is very useful in *Karnasrava*, because in later stage *Karnasrava* becomes just like *Nadivrana* and it has involvement of *Avrita Vata*.
- *Gokshuradi Ghan Vati* can be considered as the water soluble extract of *Gokshuradi Rasayana Churna*, which in the present study has demonstrated better efficacy than *Churna*. No previous literature is available citing better efficacy of *Ghana* compared to the *Churna* formulation. However in the present context a few factors can be considered which may have contributed to the better efficacy of *Ghana*. One of the reason is its better palatability than *Churna* form another is its fixed dose in the form of *Vati*/tablet. Both may have been the contributing factors for patient acceptability, while the trial group which was administered *Churna* may have found it difficult to take the proper dosage owing to its form as well as

taste. When we consider the ingredients of *Rasayana Churna* it can be found that there are no volatile ingredients in the formulation and hence the *Ghana* prepared from the *Churna* can be believed to have the actives present in *Churna* from which maintained its efficacy.

#### 2. Swarjikadya Taila

- It contains *Shudha Swarjika*, *Mulak*, *Hingu*, *Pippali*, *Sunthi* and *Shatpushpa* as *Drava Dravya* and *Taila* as base. Most of the drugs of *Swarjikadya Taila* have *Krimighna*, *Jantughna*, *Kandughna*, *Kushthaghna*, *Lekhna*, *Vishaghna*, *Vedanasthapana*, *Vranashodhana*, *Vranaropana*, *Varnyakara*, *Putihara*, *Shulaprashmana* properties. Due to these properties the *Swarjikadya Taila* relieves local pain and do *Kleda-Achushana* which helps in alleviating *Karnasrava*, and regeneration of the tympanic membrane. All the drugs of *Swarjikadya taila* have *Ushna virya*, *Katu Vipaka* and *Kapha-Vata shamaka* properties, which helps in drying up the *Srava* and elimination of *Kapha Dosh*. *Ushna* potency indicates the quick action of drug. *Pippali* has *Yogavahi* properties which help in enhancing the effect of drug. *Pippali* and *Sunthi* are strong insecticidal, which helps in elimination of local infection. *Ushna* and *Tikshna Guna* of *Swarjika* helps in drying up the *Srava*.
- It will facilitate longer residence time of drug in ear canal, thereby increases availability of drug to the tissues. Local action of *Karnapichu* is based on cellular absorption of medicine. It also absorbs the discharge or exudates from the ear which helps in quick healing process.

#### Probable Mode of Action of Karnapichu

- *Karnapichu* is a procedure where in cotton wick dipped in lukewarm oil medicated oil is inserted into the external auditory canal. In the present study, *Karnapichu* of *Swarjikadya Taila* is used in patients with C.S.O.M.
- Ear canal is cleaned thoroughly to remove the discharge and other debris which facilitates the drug absorption. The lukewarm *Swarjikadya Taila* acts as *Sthanika Snehana* and *Swedana*, thus causes increased local warming, pseudo inflammation and increased blood circulation there by helping in better absorption to affected sites. It will facilitate

longer action of drug in ear canal, thereby increases availability of drug to the tissues. Local action of *Pichu* is based on cellular absorption of medicine. It also absorbs the discharge or exudates from the ear which helps in quick healing process.

- In the present study, *Karnapichu* of *Swarjikadya Taila* is used in patients of *Karnasrava*. *Karna Pichu* is a procedure where cotton wick dipped in Luke warm oil or medicated oil is inserted into the external auditory canal. Ear canal is cleaned thoroughly to remove the discharge and other debris which facilitates the drug absorption. The lukewarm *Swarjikadya Taila* acts as *Sthanika Snehana* and *Swedana*, thus causes increased local warming, pseudo-inflammation and increased blood circulation there by helping in better absorption to affected site.
- All the drugs of *Swarjikadya taila* have *Ushna virya*, *Katu Vipaka* and *Kapha-Vatashamaka* properties, which help in drying up the *Srava* and eliminations of *Kapha Dosh*. *Ushna Virya* helps in quick action of drug. *Pippali* has *Yogavahi* properties which enhance the effect of drug. *Pippali* and *Sunthi* are strong insecticidal, which helps in elimination of local infection. *Ushna* and *Tikshna Guna* of *Swarjika* helps in drying up the *Srava*.

#### Discussion on Effect of Therapy

- **Analysis of Subjective parameters of group A:** Statistically Highly Significant (<0.001) result were found in *Karnasrava* quantity (92.30%) *Karnasrava* Consistency (92.59%) and *Karnakandu* (73.68%) and Not Significant (>0.05) result was found in *Badhirya* (20.00%).
- **Analysis of Objective parameters of group A:** Statistically Not Significant (>0.05) results were found in Objective parameters i.e., Pure Tone Audiometry (6.45%), TM Assessment (8.75%), but Significant results (<0.05) found in Swab Culture and Sensitivity, TLC, Lymphocyte, Monocytes and Basophils.
- **Analysis of Subjective parameters of group B:** Statistically Highly Significant (<0.001) result was found in *Karnasrava* Quantity (26.54%) and *Karnasrava* Consistency (46.23%), Significant (<0.05) result was found in *Karnakandu* (65.41%) and Not Significant (>0.05) result was found in *Badhirya* (7.69%) Significant results (<0.05) found in Swab Culture and Sensitivity, TLC, Lymphocyte, Monocytes and Basophils.
- **Analysis of Objective parameters of group B:** Statistically Not Significant (>0.05) results were found in Objective parameters i.e., Pure Tone Audiometry (7.69%), TM Assessment (13.63%), Significant results (<0.05) found in Swab Culture

and Sensitivity TLC, Lymphocyte, Monocytes and Basophils.

#### Intergroup comparison of Efficacy of both therapies

- **Efficacy on Quantity of *Karnasrava*:** Study shows that U value is 67.50, and P value is <0.05, that means significant, it reveals that there is statistically significant difference in efficacy of both treatments on quantity of *Karnasrava*.
- **Efficacy on Consistency of *Karnasrava*:** Present study shows that U value is 65.00 and P value is <0.05, that means significant, it reveals that there is statistically significant difference in efficacy of both treatments on consistency of *Karnasrava*.
- **Efficacy on *Badhirya*:** Present study shows U value is 112.50 and P value is >0.05, that means not significant, it shows that statistically there is no difference in both treatments on *Badhirya*.
- **Efficacy on *Karnakandu*:** Present study shows that U value is 112.50 and P value is >0.05, that means not significant, it shows that statistically there is no difference in both treatments on *Karnakandu*.

#### Intergroup comparison of efficacy of two therapies on Objective parameters of *Karnasrava*

- In the present clinical study it was observed that all the objective parameters are non-significant, it shows that statistically there is no difference in the efficacy of both treatments.

#### CONCLUSION

On the basis of clinical features *Karnasrava* can be correlated with chronic supportive otitis media having predominance of *Vata* and *Kapha Dosh*. *Karnapichu* is very effective treatment along with oral medicine in *Karnagata roga*. Both groups showed good result in the management of *Karnasrava* but *Gokshuradi Ghan vati* along with *Swarjikadya taila Karna pichu* showed slightly significant as compared to *Gokshuradi Rasayana Churna* along with *Swarjikadya Taila Karna Pichu*. *Shashti Upakrama* can be incorporated in treatment of *Karnasrava* (C.S.O.M) in further study on a larger sample.

#### REFERENCES

1. Acharya Sushruta, Sushrut Samhita with the Nibandhasangraha commentary of Sri Dalhanacharya and the Nayachandrika Pamjika of sri gayadasacharya on Nidansthan edited by Vaidya Jadavji Trikamji Acharya from the beginning to the 9<sup>th</sup> adhyaya of chikitsa sthan and rest by Narayan Ram Acharya 'Kavyatirtha', Chaukhamba surabharati prakashana, Varanasi edition 2018, Uttartantra, Karna gat rog Vigyanam Adhyay 20/3, 4, 5 Page No 643



2. Acharya Charak, Charak Samhita of Agnivesh elaborated by Carak and Drdhabala with the Ayurvedadipika commentary by Sri Cakrapanidatta edited by Vaidya Yadavaji Trikamji Acharya Prologued by Prof. R.H. Singh, Chaukhamba Surbharati Prakashan, Varanasi, Edition 2016, Chikitsasthan, Trimarmiya Adhyaya 26/127, 128 page No. 606
3. Acharya Sushruta, Sushrut Samhita with the Nibandhasangraha commentary of Sri Dalhanacharya and the Nayachandrika Pamjika of Sri gayadasacharya on Nidansthan edited by Vaidya Jadavji Trikamji Acharya from the beginning to the 9<sup>th</sup> adhyaya of chikitsa sthan and rest by Narayan Ram Acharya 'Kavyatirtha', Chaukhamba surabharati prakashana, Varanasi edition 2018, Uttartantra, Karna gat rog Vigyanam Adhyay 20/10 Page no. 644
4. Acharya Sushruta, Sushrut Samhita with the Nibandhasangraha commentary of Sri Dalhanacharya and the Nayachandrika Pamjika of sri gayadasacharya on nidansthan edited by Vaidya Jadavji Trikamji Acharya from the beginning to the 9<sup>th</sup> adhyaya of chikitsa sthan and rest by Narayan Ram Acharya Kavyatirtha, Chaukhamba surabharati prakashana, Varanasi edition 2018, Uttartantra, Karna gat rog Vigyanam Adhyay 20/10 Page no. 647
5. Acharya Sushruta, Sushrut Samhita with the Nibandhasangraha commentary of Sri Dalhanacharya and the Nayachandrika Pamjika of sri gayadasacharya on nidansthan edited by Vaidya Jadavji Trikamji Acharya from the beginning to the 9<sup>th</sup> adhyaya of chikitsa sthan and rest by Narayan Ram Acharya Kavyatirtha, Chaukhamba surabharati prakashana, Varanasi edition 2018, Uttartantra, Karna gat rog Vigyanam Adhyay 20/10 Page no. 644
6. Chronic suppurative otitis media Burden of Illness and Management Options <https://apps.who.int/iris/bitstream/handle/10665/42941/9241591587.pdf>
7. Nagar M, Pamanani GC, Soni RK. A Randomized Clinical trial of Karnapichu with Gandhaka Taila, Karna Dhupana and Rasanadi Guggulu in the management of Karnasrava w.s.r. to Chronic Supportive Otitis Media. J Ayurveda 2021; 15: 249-54
8. Acharya Vagbhata, Astang Hridayam with the commentaries of Arunadatta and Hemadri, collated by Late Dr. Anna Moreshwar kunte and Krishna Ramchandra shastri Navare, edited by Bhisagacharya Harisastri Paradakara Vaidya Introduction by Prof. P.V. Sharma, Chaukhamba Orientalia, Varanasi, Uttarsthan, Rasayanvidhi adhyaya, 39/159, Page No-937
9. Acharya Vagbhata, Astang Hridayam with the commentaries of Arunadatta and Hemadri, collated by Late Dr. Anna Moreshwar kunte and Krishna Ramchandra shastri Navare, edited by Bhisagacharya Harisastri Paradakara Vaidya Introduction by Prof. P.V. Sharma, Chaukhamba Orientalia, Varanasi, Uttarsthan, Rasayanvidhi adhyaya, 39/159, Page No-937
10. Kaviraj Govind Das Sen Siddinandan Mishra by Prof. Siddhi Nandan Mishra, Bhaishajya Ratnavali Chaukhamba Sanskrit Pratishtan Delhi, Karnaroga chikitsa- 62/27
11. Bhanu pratap singh and Deepa, International Ayurveda Medical Journal-Review article, on Concept of immuno-modulaion in Ayurveda and some immunomodulatory herbs. Volume 3, Issue 7, July 2015-Page No 2205-2212

**Cite this article as:**

Seema Yadav, Gulab Chand Pamnani, Aparna Sharma. A Randomized Clinical Trial of Gokshuradi Ghan Vati and Gokshuradi Rasayana Churna along with Swarjikadya Taila Karna Pichu in the Management of Karnasrava With Special Reference to Chronic Suppurative Otitis Media. AYUSHDHARA, 2023;10(Suppl 1):27-35.

<https://doi.org/10.47070/ayushdhara.v10iSuppl1.1168>

**Source of support: Nil, Conflict of interest: None Declared**

**\*Address for correspondence**

**Dr. Seema Yadav**

Assistant Professor,  
Dept of Shalakyta Tantra,  
Punjab Ayurved Medical College  
and Hospital, Morjand Khari, Sri  
Ganganagar, Rajasthan.

Email: [drseema1989@gmail.com](mailto:drseema1989@gmail.com)

Mob: 8529347162

Disclaimer: AYUSHDHARA is solely owned by Mahadev Publications - A non-profit publications, dedicated to publish quality research, while every effort has been taken to verify the accuracy of the content published in our Journal. AYUSHDHARA cannot accept any responsibility or liability for the articles content which are published. The views expressed in articles by our contributing authors are not necessarily those of AYUSHDHARA editor or editorial board members.